Skip to main content

Table 2 IMR data and cytokine levels

From: The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease

  Patient group vs control group Patient group
Controls (N = 26) Patients (N = 74) P aMCI (N = 35) AD (N = 39) P
1-40 50.7 ± 4.9 52.1 ± 4.2 0.160 51.9 ± 4.8 52.3 ± 3.7 0.654
1-42 16.9 ± 0.7 17.3 ± 1.0 0.038 17.2 ± 1.1 17.4 ± 0.9 0.455
t-Tau 23.8 ± 3.9 26.6 ± 5.1 0.014 26.0 ± 5.1 27.1 ± 5.2 0.374
p-Tau181 3.7 ± 0.7 4.1 ± 0.9 0.035 4.0 ± 0.9 4.2 ± 0.9 0.340
IL-1β 0.07 ± 0.04 0.12 ± 0.11 0.039 0.12 ± 0.11 0.12 ± 0.12 0.765
IL-1RA 63 ± 31 96 ± 79 0.045 108 ± 104 85 ± 45 0.289
  1. Abbreviation: aMCI mild cognitive impairment due to Alzheimer’s disease, AD Alzheimer’s disease, IL interleukin; IL-1RA interleukin 1 receptor antagonist